These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 2869001)

  • 1. Controlled trial on three beta-blockers: antihypertensive efficacy and effect on the hypertensive heart disease.
    Pupita F; Ansuini R; Belogi M; Pupita G; Gaggi S
    Int J Clin Pharmacol Res; 1985; 5(6):439-45. PubMed ID: 2869001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Catecholamines and heart function in heart transplant patients: effects of beta1- versus nonselective beta-blockade.
    Leenen FH; Davies RA; Fourney A
    Clin Pharmacol Ther; 1998 Nov; 64(5):522-35. PubMed ID: 9834044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of atenolol and oxprenolol in the treatment of arterial hypertension. A comparison.
    Turner AS; Watson OF; Brocklehurst JE
    Med J Aust; 1979 Jun; 1(13):625-6. PubMed ID: 386061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
    Okin PM; Wachtell K; Kjeldsen SE; Julius S; Lindholm LH; Dahlöf B; Hille DA; Nieminen MS; Edelman JM; Devereux RB
    Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):337-43. PubMed ID: 19808428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term reduction of peripheral resistance with celiprolol and effects on left ventricular mass.
    Trimarco B; Lembo G; DeLuca N; Ricciardelli B; Rosiello G; Volpe M; Orofino G; Condorelli M
    J Int Med Res; 1988; 16 Suppl 1():62A-72A. PubMed ID: 2906018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacology of hypertension: amelioration of left ventricular performance by treatment with labetalol.
    Belogi M; Ansuini R; Pupita G; Campolucci G; Pupita F
    Int J Clin Pharmacol Res; 1984; 4(5):385-7. PubMed ID: 6519853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of talinolol and atenolol effects on blood pressure in relation to lipid and glucose metabolic parameters. Results from the TALIP study.
    Sourgens H; Schmidt J; Derendorf H
    Int J Clin Pharmacol Ther; 2003 Jan; 41(1):22-9. PubMed ID: 12564742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and safety of different beta-blockers in patients with isolated systolic hypertension associated with diabetes mellitus and obstructive pulmonary diseases].
    Kukes VG; Ostroumova OD; Mamaev VI; Batutina AM; Abakumov IuE; Zykova AA
    Ter Arkh; 2003; 75(8):43-7. PubMed ID: 14520850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihypertensive and renal haemodynamic effects of atenolol and nadolol in elderly hypertensive patients.
    O'Callaghan WG; Laher MS; McGarry K; O'Brien E; O'Malley K
    Br J Clin Pharmacol; 1983 Oct; 16(4):417-21. PubMed ID: 6138058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of 4 beta-adrenoceptor blocking drugs on blood pressure and exercise heart rate in hypertension.
    Harry JD; Knapp MF; Linden RJ; Stoker JB; Newcombe C
    Eur J Cardiol; 1979 Aug; 10(2):131-41. PubMed ID: 38965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twenty-four-hour ambulatory blood pressure monitoring efficacy of perindopril/indapamide first-line combination in hypertensive patients: the REASON study.
    Mallion JM; Chamontin B; Asmar R; De Leeuw PW; O'Brien E; Duprez D; O'Rourke MF; Rahn KH; Romero R; Battegay E; Hitzenberger G; Safar ME;
    Am J Hypertens; 2004 Mar; 17(3):245-51. PubMed ID: 15001199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction of hypertensive cardiac remodelling: comparison of different antihypertensive therapies.
    Almazov VA; Shlyakhto EV; Konrady AO; Macsimova TA; Zaharov DV; Rudomanov OG
    Med Sci Monit; 2000; 6(2):309-13. PubMed ID: 11208328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Field study: long-term antihypertensive therapy with the beta blocker nadolol in a once-a-day dosage - an outpatient study of Swiss medical practices].
    Bertel O; Conen D; Renggli I
    Schweiz Rundsch Med Prax; 1983 Feb; 72(8):264-8. PubMed ID: 6132374
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison between atenolol and nadolol in essential hypertension at rest and on exercise.
    Wilcox RG; Hampton JR
    Br J Clin Pharmacol; 1982 Jun; 13(6):841-6. PubMed ID: 6124268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and hemodynamic effects of celiprolol in essential hypertension.
    Parati G; Ravogli A; Bragato R; Omboni S; Mutti E; Mancia G
    J Cardiovasc Pharmacol; 1989; 14 Suppl 7():S14-21. PubMed ID: 2481785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical study of the beta-blocker chlorpropanol (tobanum) in hypertension patients].
    Sirakova V; Penkov N; Kaponov Kh
    Vutr Boles; 1986; 25(1):35-41. PubMed ID: 2872751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Field trial with a new betablocker (Solgol)].
    Piergies A; Schimert G
    MMW Munch Med Wochenschr; 1980 Oct; 122(42):1473-6. PubMed ID: 6110182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Wachtell K; Lehto M; Gerdts E; Olsen MH; Hornestam B; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Devereux RB
    J Am Coll Cardiol; 2005 Mar; 45(5):712-9. PubMed ID: 15734615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 16-week, randomized, double-blind, placebo-controlled, crossover trial to quantify the combined effect of an angiotensin-converting enzyme inhibitor and a beta-blocker on blood pressure reduction.
    Wald DS; Law M; Mills S; Bestwick JP; Morris JK; Wald NJ
    Clin Ther; 2008 Nov; 30(11):2030-9. PubMed ID: 19108791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.